Evaluating Response to High‐Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's Disease

Documenti analoghi

• A 24‐Week, Randomized, Controlled Trial of Rivastigmine Patch 13.3 mg/24 h Versus 4.6 mg/24 h in Severe Alzheimer's Dementia
  di: Farlow, Martin R., et al.
  Pubblicazione: (2013)
• Efficacy of 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch on activities of daily living in severe Alzheimer’s disease
  di: Micca, Joseph L, et al.
  Pubblicazione: (2014)
• Rivastigmine From Capsules to Patch: Therapeutic Advances in the Management of Alzheimer’s Disease and Parkinson’s Disease Dementia
  di: Sadowsky, Carl H., et al.
  Pubblicazione: (2014)
• Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch
  di: Molinuevo, José L, et al.
  Pubblicazione: (2015)
• Switching From Oral Donepezil to Rivastigmine Transdermal Patch in Alzheimer's Disease: 20-Week Extension Phase Results
  di: Sadowsky, Carl H., et al.
  Pubblicazione: (2010)